[1]
|
Consensus Development Conference on Osteoporosis. Hong Kong, April 1-2, 1993. American Journal of Medicine, 95, 1S-78S.
|
[2]
|
Kanis, J.A. (2008) Assessment of Osteoporosis at the Primary Health Care Level. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School; Printed by the University of Sheffield, 6 p.
|
[3]
|
Wright, N.C., Looker, A.C., Saag, K.G. and Jeffrey, R. (2014) The Recent Prevalence of Osteoporosis and Low Bone Mass in the United States Based on Bone Mineral Density at the Femoral Neck or Lumbar Spine. Journal of Bone and Mineral Research, 29, 2520-2526. https://doi.org/10.1002/jbmr.2269
|
[4]
|
Riggs, B.L. and Melton 3rd, L.J. (1986) Involutional Osteoporosis. The New England Journal of Medicine, 314, 1676-1686. https://doi.org/10.1056/NEJM198606263142605
|
[5]
|
Melton 3rd, L.J., Thamer, M., Ray, N.F., Chan, J.K., Chesnut 3rd, C.H., Einhorn, T.A., et al. (1997) Fractures Attributable to Osteoporosis: Report from the National Osteoporosis Foundation. Journal of Bone and Mineral Research, 12, 16-23. https://doi.org/10.1359/jbmr.1997.12.1.16
|
[6]
|
Genant, H., Cooper, C., Poor, G. and Reid, I.R. (1999) Interim Report and Recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporosis International, 10, 259-264. https://doi.org/10.1007/s001980050224
|
[7]
|
Chung, H.Y., Sung, B., Jung, K.J., Zou, Y. and Yu, B.P. (2006) The Molecular Inflammatory Process in Aging. Antioxidants & Redox Signaling, 8, 572-581. https://doi.org/10.1089/ars.2006.8.572
|
[8]
|
Rivadeneira, F., Styrkarsdottir, U., Estrada, K., Halldorsson, B.V., Hsu, Y.-H., Richards, J.B., et al. (2009) Twenty Bone-Mineral-Density Loci Identified by Large-Scale Meta-Analysis of Genome-Wide Association Studies. Nature Genetics, 41, 1199-1206. https://doi.org/10.1038/ng.446
|
[9]
|
Shabestari, M. and Eriksen, E.F. (2013) Mechanisms of Bone Remodeling. In: Stovall, D.W., Ed., Osteoporosis, John Wiley & Sons, Ltd., Hoboken, 31-45. https://doi.org/10.1002/9781118316290.ch3
|
[10]
|
Lindsay, R., Hart, D.M., Forrest, C. and Baird, C. (1980) Prevention of Spinal Osteoporosis in Oophorectomised Women. Lancet, 2, 1151-1154. https://doi.org/10.1016/S0140-6736(80)92592-1
|
[11]
|
Recker, R.R., Kimmel, D.B., Parfitt, A.M., Davies, K.M., Keshawarz, N. and Hinders, S. (1988) Static and Tetracycline-Based Bone Histomorphometric Data from 34 Normal Postmenopausal Females. Journal of Bone and Mineral Research, 3, 133-144. https://doi.org/10.1002/jbmr.5650030203
|
[12]
|
Pacifici, R., Rifas, L., Teitelbaum, S., Slatopolsky, E., McCracken, R., Bergfeld, M., et al. (1987) Spontaneous Release of Interleukin 1 from Human Blood Monocytes Reflects Bone Formation in Idiopathic Osteoporosis. Proceedings of the National Academy of Sciences of the United States of America, 84, 4616-4620. https://doi.org/10.1073/pnas.84.13.4616
|
[13]
|
Adler, R.A. (2014) Osteoporosis in Men: A Review. Bone Research, 2, Article No. 14001. https://doi.org/10.1038/boneres.2014.1
|
[14]
|
Painter, S.E., Kleerekoper, M. and Camacho, P.M. (2006) Secondary Osteoporosis: A Review of the Recent Evidence. Endocrine Practice, 12, 436-445.
|
[15]
|
Fitzpatrick, L.A. (2002) Secondary Causes of Osteoporosis. Mayo Clinic Proceedings, 77, 453-468. https://doi.org/10.1016/S0025-6196(11)62214-3
|
[16]
|
Montagnani, A. (2014) Bone Anabolics in Osteoporosis: Actuality and Perspectives. World Journal of Orthopedics, 5, 247-254. https://doi.org/10.5312/wjo.v5.i3.247
|
[17]
|
Srivastava, M. and Deal, C. (2002) Osteoporosis in Elderly: Prevention and Treatment. Clinics in Geriatric Medicine, 18, 529-555. https://doi.org/10.1016/S0749-0690(02)00022-8
|
[18]
|
Ivanova, S., Vasileva, L., Ivanova, S., Peikova, L. and Obreshkova, D. (2015) Osteoporosis: Therapeutic Options. Folia Medica, 57, 181-190.
|
[19]
|
Watts, N.B. and Diab, D.L. (2010) Long-Term Use of Bisphosphonates in Osteoporosis. The Journal of Clinical Endocrinology & Metabolism, 95, 1555-1565. https://doi.org/10.1210/jc.2009-1947
|
[20]
|
Ebetino, F.H., Hogan, A.-M.L., Sun, S., Tsoumpra, M.K., Duan, X., Triffitt, J.T., et al. (2011) The Relationship between the Chemistry and Biological Activity of the Bisphosphonates. Bone, 49, 20-33. https://doi.org/10.1016/j.bone.2011.03.774
|
[21]
|
Graham, R. and Russell, G. (2011) Bisphosphonates: The First 40 Years. Bone, 49, 2-19. https://doi.org/10.1016/j.bone.2011.04.022
|
[22]
|
Powles, T., Paterson, A., McCloskey, E., Schein, P., Scheffler, B., Tidy, A., et al. (2006) Reduction in Bone Relapse and Improved Survival with Oral Clodronate for Adjuvant Treatment of Operable Breast Cancer. Breast Cancer Research, 8, R13. https://doi.org/10.1186/bcr1384
|
[23]
|
Miller, P.D. and Watts, N.B. (2013) Bisphosphonates. In: Stovall, D.W., Ed., Osteoporosis: Diagnosis and Management, John Wiley & Sons, Ltd., Hoboken, 123-143. https://doi.org/10.1002/9781118316290.ch9
|
[24]
|
Giger, E.V., Castagner, B. and Leroux, J.-C. (2013) Biomedical Applications of Bisphosphonates. Journal of Controlled Release, 167, 175-188. https://doi.org/10.1016/j.jconrel.2013.01.032
|
[25]
|
Ezra, A. and Golomb, G. (2000) Administration Routes and Delivery Systems of Bisphosphonates for the Treatment of Bone Resorption. Advanced Drug Delivery Reviews, 42, 175-195. https://doi.org/10.1016/S0169-409X(00)00061-2
|
[26]
|
Dunn, C.J. and Goa, K.L. (2001) Risedronate: A Review of Its Pharmacological Properties and Clinical Use in Resorptive Bone Disease. Drugs, 61, 685-712. https://doi.org/10.2165/00003495-200161050-00013
|
[27]
|
Roemer-Becuwe, C., Vigano, A., Romano, F., Neumann, C., Hanson, J., Quan, H.K., et al. (2003) Safety of Subcutaneous Clodronate and Efficacy in Hypercalcemia of Malignancy: A Novel Route of Administration. Journal of Pain and Symptom Management, 26, 843-848. https://doi.org/10.1016/S0885-3924(03)00252-5
|
[28]
|
Rogers, M.J., Crockett, J.C., Coxon, F.P. and Monkkonen, J. (2011) Biochemical and Molecular Mechanisms of Action of Bisphosphonates. Bone, 49, 34-41. https://doi.org/10.1016/j.bone.2010.11.008
|
[29]
|
Cremers, S. and Papapoulos, S. (2011) Pharmacology of Bisphosphonates. Bone, 49, 42-49. https://doi.org/10.1016/j.bone.2011.01.014
|
[30]
|
Russell, R.G., Watts, N.B., Ebetino, F.H. and Rogers, M.J. (2008) Mechanisms of Action of Bisphosphonates: Similarities and Differences and Their Potential Influence on Clinical Efficacy. Osteoporosis International, 19, 733-759. https://doi.org/10.1007/s00198-007-0540-8
|
[31]
|
Drake, M.T. and Cremers, S.C.L.M. (2010) Bisphosphonate Therapeutics in Bone Disease: The Hard and Soft Data on Osteoclast Inhibition. Molecular Interventions, 10, 141-152. https://doi.org/10.1124/mi.10.3.5
|
[32]
|
Khan, S.A., Kanis, J.A., Vasikaran, S., Kline, W.F., Matuszewski, B.K., McCloskey, E.V., et al. (1997) Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis. Journal of Bone and Mineral Research, 12, 1700-1707. https://doi.org/10.1359/jbmr.1997.12.10.1700
|
[33]
|
Russell, R.G., Muhlbauer, R.C., Bisaz, S., Williams, D.A. and Fleisch, H. (1970) The Influence of Pyrophosphate, Condensed Phosphates, Phosphonates and Other Phosphate Compounds on the Dissolution of Hydroxyapatite in Vitro and on Bone Resorption Induced by Parathyroid Hormone in Tissue Culture and in Thyroparathyroidectomised Rats. Calcified Tissue Research, 6, 183-196. https://doi.org/10.1007/BF02196199
|
[34]
|
Roelofs, A.J., Coxon, F.P., Ebetino, F.H., Lundy, M.W., Henneman, Z.J., Nancollas, G.H., et al. (2010) Fluorescent Risedronate Analogues Reveal Bisphosphonate Uptake by Bone Marrow Monocytes and Localization around Osteocytes in Vivo. Journal of Bone and Mineral Research, 25, 606-616. https://doi.org/10.1359/jbmr.091009
|
[35]
|
Coxon, F.P., Thompson, K., Roelofs, A.J., Ebetino, F.H. and Rogers, M.J. (2008) Visualizing Mineral Binding and Uptake of Bisphosphonate by Osteoclasts and Non-Resorbing Cells. Bone, 42, 848-860. https://doi.org/10.1016/j.bone.2007.12.225
|
[36]
|
Rogers, M.J., Frith, J.C., Luckman, S.P., Coxon, F.P., Benford, H.L., Monkkonen, J., et al. (1999) Molecular Mechanisms of Action of Bisphosphonates. Bone, 24, 73S-79S. https://doi.org/10.1016/S8756-3282(99)00070-8
|
[37]
|
Bellido, T. and Plotkin, L.I. (2011) Novel Actions of Bisphosphonates in Bone: Preservation of Osteoblast and Osteocyte Viability. Bone, 49, 50-55. https://doi.org/10.1016/j.bone.2010.08.008
|
[38]
|
Frith, J.C., Monkkonen, J., Auriola, S., Monkkonen, H. and Rogers, M.J. (2001) The Molecular Mechanism of Action of the Antiresorptive and Antiinflammatory Drug Clodronate: Evidence for the Formation in Vivo of a Metabolite That Inhibits Bone Resorption and Causes Osteoclast and Macrophage Apoptosis. Arthritis & Rheumatology, 44, 2201-2210. https://doi.org/10.1002/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E
|
[39]
|
Hiroi-Furuya, E., Kameda, T., Hiura, K., Mano, H., Miyazawa, K., Nakamaru, Y., et al. (1999) Etidronate (EHDP) Inhibits Osteoclastic-Bone Resorption, Promotes Apoptosis and Disrupts Actin Rings in Isolate-Mature Osteoclasts. Calcified Tissue International, 64, 219-223. https://doi.org/10.1007/s002239900606
|
[40]
|
Sato, M. and Grasser, W. (1990) Effects of Bisphosphonates on Isolated Rat Osteoclasts as Examined by Reflected Light Microscopy. Journal of Bone and Mineral Research, 5, 31-40. https://doi.org/10.1002/jbmr.5650050107
|
[41]
|
Coxon, F.P., Helfrich, M.H., Larijani, B., Muzylak, M., Dunford, J.E., Marshall, D., et al. (2001) Identification of a Novel Phosphonocarboxylate Inhibitor of Rab Geranylgeranyl Transferase That Specifically Prevents Rab Prenylation in Osteoclasts and Macrophages. The Journal of Biological Chemistry, 276, 48213-48222. https://doi.org/10.1074/jbc.M106473200
|
[42]
|
Zhang, F.L. and Casey, P.J. (1996) Protein Prenylation: Molecular Mechanisms and Functional Consequences. Annual Review of Biochemistry, 65, 241-269. https://doi.org/10.1146/annurev.bi.65.070196.001325
|
[43]
|
Dunford, J.E., Thompson, K., Coxon, F.P., Luckman, S.P., Hahn, F.M., Poulter, C.D., et al. (2001) Structure-Activity Relationships for Inhibition of Farnesyl Diphosphate Synthase in Vitro and Inhibition of Bone Resorption in Vivo by Nitrogen-Containing Bisphosphonates. Journal of Pharmacology and Experimental Therapeutics, 296, 235-242.
|
[44]
|
Coxon, F.P. and Rogers, M.J. (2003) The Role of Prenylated Small GTP-Binding Proteins in the Regulation of Osteoclast Function. Calcified Tissue International, 72, 80-84. https://doi.org/10.1007/s00223-002-2017-2
|
[45]
|
Bergstrom, J.D., Bostedor, R.G., Masarachia, P.J., Reszka, A.A. and Rodan, G. (2000) Alendronate Is a Specific, Nanomolar Inhibitor of Farnesyl Diphosphate Synthase. Archives of Biochemistry and Biophysics, 373, 231-241. https://doi.org/10.1006/abbi.1999.1502
|
[46]
|
Plotkin, L.I., Weinstein, R.S., Parfitt, A.M., Roberson, P.K., Manolagas, S.C. and Bellido, T. (1999) Prevention of Osteocyte and Osteoblast Apoptosis by Bisphosphonates and Calcitonin. The Journal of Clinical Investigation, 104, 1363-1374. https://doi.org/10.1172/JCI6800
|
[47]
|
Abe, Y., Kawakami, A., Nakashima, T., Ejima, E., Fujiyama, K., Kiriyama, T., et al. (2000) Etidronate Inhibits Human Osteoblast Apoptosis by Inhibition of Pro-Apoptotic Factor(s) Produced by Activated T Cells. Journal of Laboratory and Clinical Medicine, 136, 344-354. https://doi.org/10.1067/mlc.2000.109757
|
[48]
|
Plotkin, L.I., Lezcano, V., Thostenson, J., Weinstein, R.S., Manolagas, S.C. and Bellido, T. (2008) Connexin 43 Is Required for the Anti-Apoptotic Effect of Bisphosphonates on Osteocytes and Osteoblasts in Vivo. Journal of Bone and Mineral Research, 23, 1712-1721. https://doi.org/10.1359/jbmr.080617
|
[49]
|
Fromigue, O. and Body, J.J. (2002) Bisphosphonates Influence the Proliferation and the Maturation of Normal Human Osteoblasts. Journal of Endocrinological Investigation, 25, 539-546. https://doi.org/10.1007/BF03345497
|
[50]
|
Frediani, B., Spreafico, A., Capperucci, C., Chellini, F., Gambera, D., Ferrata, P., et al. (2004) Long-Term Effects of Neridronate on Human Osteoblastic Cell Cultures. Bone, 35, 859-869. https://doi.org/10.1016/j.bone.2004.06.001
|
[51]
|
Nishikawa, M., Akatsu, T., Katayama, Y., Yasutomo, Y., Kado, S., Kugal, N., et al. (1996) Bisphosphonates Act on Osteoblastic Cells and Inhibit Osteoclast Formation in Mouse Marrow Cultures. Bone, 18, 9-14. https://doi.org/10.1016/8756-3282(95)00426-2
|
[52]
|
Viereck, V., Emons, G., Lauck, V., Frosch, K.-H., Blaschke, S., Grundker, C., et al. (2002) Bisphosphonates Pamidronate and Zoledronic Acid Stimulate Osteoprotegerin Production by Primary Human Osteoblasts. Biochemical and Biophysical Research Communications, 291, 680-686. https://doi.org/10.1006/bbrc.2002.6510
|
[53]
|
Pan, B., Farrugia, A.N., To, L.B., Findlay, D.M., Green, J., Lynch, K., et al. (2004) The Nitrogen-Containing Bisphosphonate, Zoledronic Acid, Influences RANKL Expression in Human Osteoblast-Like Cells by Activating TNF-Alpha Converting Enzyme (TACE). Journal of Bone and Mineral Research, 19, 147-154. https://doi.org/10.1359/jbmr.2004.19.1.147
|
[54]
|
Nanci, A. (2013) Ten Cate’s Oral Histology: Development, Structure and Function. 8th Edition, Elsevier Mosby, St Louis, 81-83.
|
[55]
|
Khosla, S., Burr, D., Cauley, J., Dempster, D.W., Ebeling, P.R., Felsenberg, D., et al. (2007) Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 22, 1479-1491. https://doi.org/10.1359/jbmr.0707onj
|
[56]
|
Ruggiero, S.L., Mehrotra, B., Rosenberg, T.J. and Engroff, S.L. (2004) Osteonecrosis of the Jaws Associated with the Use of Bisphosphonates: A Review of 63 Cases. Journal of Oral and Maxillofacial Surgery, 62, 527-534. https://doi.org/10.1016/j.joms.2004.02.004
|
[57]
|
Sharma, D., Ivanovski, S., Slevin, M., Hamlet, S., Pop, T.S., Brinzaniuc, K., et al. (2013) Bisphosphonate-Related Osteonecrosis of Jaw (BRONJ): Diagnostic Criteria and Possible Pathogenic Mechanisms of an Unexpected Anti-Angiogenic Side Effect. Vascular Cell, 5, 1. https://doi.org/10.1186/2045-824X-5-1
|
[58]
|
Tsao, C., Darby, I., Ebeling, P.R., Walsh, K., O’Brien-Simpson, N., Reynolds, E., et al. (2013) Oral Health Risk Factors for Bisphosphonate-Associated Jaw Osteonecrosis. Journal of Oral and Maxillofacial Surgery, 71, 1360-1366. https://doi.org/10.1016/j.joms.2013.02.016
|
[59]
|
Barasch, A., Cunha-Cruz, J., Curro, F., DeRouen, T., Gilbert, G.H., Hujoel, P., et al. (2013) Dental Risk Factors for Osteonecrosis of the Jaws: A CONDOR Case-Control Study. Clinical Oral Investigations, 17, 1839-1845. https://doi.org/10.1007/s00784-012-0880-4
|
[60]
|
Khan, A.A., Morrison, A., Hanley, D.A., Felsenberg, D., McCauley, L.K., O’Ryan, F., et al. (2015) Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus. Journal of Bone and Mineral Research, 30, 3-23. https://doi.org/10.1002/jbmr.2405
|
[61]
|
Cartsos, V.M., Zhu, S. and Zavras, A.I. (2008) Bisphosphonate Use and the Risk of Adverse Jaw Outcomes: A Medical Claims Study of 714,217 People. The Journal of the American Dental Association, 139, 23-30. https://doi.org/10.14219/jada.archive.2008.0016
|
[62]
|
Reid, I.R. (2009) Osteonecrosis of the Jaw: Who Gets It, and Why? Bone, 44, 4-10. https://doi.org/10.1016/j.bone.2008.09.012
|
[63]
|
Odvina, C.V., Levy, S., Rao, S., Zerwekh, J.E. and Rao, D.S. (2010) Unusual Mid-Shaft Fractures during Long-Term Bisphosphonate Therapy. Clinical Endocrinology, 72, 161-168. https://doi.org/10.1111/j.1365-2265.2009.03581.x
|
[64]
|
Mashiba, T., Turner, C.H., Hirano, T., Forwood, M.R., Johnston, C.C. and Burr, D.B. (2001) Effects of Suppressed Bone Turnover by Bisphosphonates on Microdamage Accumulation and Biomechanical Properties in Clinically Relevant Skeletal Sites in Beagles. Bone, 28, 524-531. https://doi.org/10.1016/S8756-3282(01)00414-8
|
[65]
|
Allen, M.R., Iwata, K., Phipps, R. and Burr, D.B. (2006) Alterations in Canine Vertebral Bone Turnover, Microdamage Accumulation, and Biomechanical Properties Following 1-Year Treatment with Clinical Treatment Doses of Risedronate or Alendronate. Bone, 39, 872-879. https://doi.org/10.1016/j.bone.2006.04.028
|
[66]
|
Nancollas, G.H., Tang, R., Phipps, R.J., Henneman, Z., Gulde, S. and Wu, W. (2006) Novel Insights into Actions of Bisphosphonates on Bone: Differences in Interactions with Hydroxyapatite. Bone, 38, 617-627. https://doi.org/10.1016/j.bone.2005.05.003
|
[67]
|
Schnitzer, T., Bone, H.G., Crepaldi, G., Adami, S., McClung, M., Kiel, D., et al. (2000) Therapeutic Equivalence of Alendronate 70 mg Once-Weekly and Alendronate 10 mg Daily in the Treatment of Osteoporosis. Alendronate Once-Weekly Study Group. Aging, 12, 1-12.
|
[68]
|
Ralston, S. (2015) Bisphosphonates for Osteoporosis. In: Harrison-Woolrych, M., Ed., Medicines for Women, 2015th Edition, Springer International Publishing, Cham, 345-371. https://doi.org/10.1007/978-3-319-12406-3_12
|
[69]
|
Mackay Lvwilton, F.J., Pearce, G.L., Freemantle, S.N. and Mann, R.D. (1998) United Kingdom Experience with Alendronate and Oesophageal Reactions. British Journal of General Practice, 48, 1161-1162.
|
[70]
|
Black, D.M., Reiss, T.E., Nevitt, M.C., Cautey, J., Karpf, D. and Cummings, S.R. (1993) Design of the Fracture Intervention Trial. Osteoporosis International, 3, 29-39. https://doi.org/10.1007/BF01623005
|
[71]
|
Black, D.M., Cummings, S.R., Karpf, D.B., Cauley, J.A., Thompson, D.E., Nevitt, M.C., et al. (1996) Randomised Trial of Effect of Alendronate on Risk of Fracture in Women with Existing Vertebral Fractures. The Lancet, 348, 1535-1541. https://doi.org/10.1016/S0140-6736(96)07088-2
|
[72]
|
Cummings, S.R., Black, D.M., Thompson, D.E., Applegate, W.B., Barrett-Connor, E., Musliner, T.A., et al. (1998) Effect of Alendronate on Risk of Fracture in Women with Low Bone Density but without Vertebral Fractures Results from the Fracture Intervention Trial. JAMA, 280, 2077-2082. https://doi.org/10.1001/jama.280.24.2077
|
[73]
|
Black, D.M., Thompson, D.E., Bauer, D.C., Ensrud, K., Musliner, T., Hochberg, M.C., et al. (2000) Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial. JCEM, 85, 4118-4124.
|
[74]
|
Hochberg, M.C., Ross, P.D., Black, D., Cummings, S.R., Genant, H.K., Nevitt, M.C., et al. (1999) Larger Increases in Bone Mineral Density during Alendronate Therapy Are Associated with a Lower Risk of New Vertebral Fractures in Women with Postmenopausal Osteoporosis. Arthritis & Rheumatology, 42, 1246-1254. https://doi.org/10.1002/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U
|
[75]
|
Black, D.M., Schwartz, A.V., Ensrud, K.E., et al. (2006) Effects of Continuing or Stopping Alendronate after 5 Years of Treatment. The Fracture Intervention Trial Long-Term Extension (FLEX): A Randomized Trial. JAMA, 296, 2927-2938. https://doi.org/10.1001/jama.296.24.2927
|
[76]
|
Tucci, J.R., Tonino, R.P., Emkey, R.D., Peverly, C.A., Kher, U., Ii, A.C.S., et al. (1996) Effect of Three Years of Oral Alendronate Treatment Postmenopausal in Women with Osteoporosis. The American Journal of Medicine, 101, 488-501. https://doi.org/10.1016/S0002-9343(96)00282-3
|
[77]
|
Liberman, U.A., Weiss, S.R., Bröll, J., Minne, H.W., Quan, H., Bell, N.H., et al. (1995) Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis. The New England Journal of Medicine, 333, 1437-1443. https://doi.org/10.1056/NEJM199511303332201
|
[78]
|
Favus, M., Emkey, R., Leite, M., Devogelaer, J.P., Rodriguez, J., Peverly, C., Kaur, S.A. (1997) Five-Year Treatment of Osteoporosis in Postmenopausal Women with Oral Alendronate: Effects on Bone Mass and Turnover and Safety. Journal of Bone and Mineral Research, 12, 189.
|
[79]
|
Tonino, R.P., Meunier, P.J., Emkey, R., Rodriguez-Portales, J.A., Menkes, C., Wasnich, R.D., et al. (2000) Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women. The Journal of Clinical Endocrinology & Metabolism, 85, 3109-3115. https://doi.org/10.1210/jc.85.9.3109
|
[80]
|
Tucci, J.R., Emkey, R.D., Tonino, R.P., Rodriguez-Portales, J.A., Downs, R.W., Gupta, J., et al. (2004) Ten Years’ Experience with Alendronate for Osteoporosis in Postmenopausal Women. The New England Journal of Medicine, 350, 1189-1199.
|
[81]
|
Cranney, A.N.N., Wells, G., Willan, A., Griffith, L., Zytaruk, N., Robinson, V., et al. (2002) II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women. Endocrine Reviews, 23, 508-516. https://doi.org/10.1210/er.2001-2002
|
[82]
|
Papapoulos, S.E., Quandt, S.A., Liberman, U.A., Hochberg, M.C. and Thompson, D.E. (2005) Meta-Analysis of the Efficacy of Alendronate for the Prevention of Hip Fractures in Postmenopausal Women. Osteoporosis International, 16, 468-474. https://doi.org/10.1007/s00198-004-1725-z
|
[83]
|
Woo, S.-B., Hellstein, J.W. and Kalmar, J.R. (2006) Narrative Review: Bisphosphonates and Osteonecrosis of the Jaws. Annals of Internal Medicine, 144, 753-761. https://doi.org/10.7326/0003-4819-144-10-200605160-00009
|
[84]
|
Schilcher, J., Michaelsson, K. and Aspenberg, P. (2011) Bisphosphonate Use and Atypical Fractures of the Femoral Shaft. The New England Journal of Medicine, 364, 1728-1737. https://doi.org/10.1056/NEJMoa1010650
|
[85]
|
Leu, C., Luegmayr, E., Freedman, L.P., Rodan, G.A. and Reszka, A.A. (2006) Relative Binding Affinities of Bisphosphonates for Human Bone and Relationship to Antiresorptive Efficacy. Bone, 38, 628-636. https://doi.org/10.1016/j.bone.2005.07.023
|
[86]
|
Gasser, J.A., Ingold, P., Venturiere, A., Shen, V. and Green, J.R. (2008) Long-Term Protective Effects of Zoledronic Acid on Cancellous and Cortical Bone in the Ovariectomized Rat. Journal of Bone and Mineral Research, 23, 544-551. https://doi.org/10.1359/jbmr.071207
|
[87]
|
Grey, A., Bolland, M., Wattie, D., Horne, A., Gamble, G. and Reid, I.R. (2010) Prolonged Antiresorptive Activity of Zoledronate. Journal of Bone and Mineral Research, 25, 2251-2255. https://doi.org/10.1002/jbmr.103
|
[88]
|
Black, D.M., Delmas, P.D., Eastell, R., Reid, I.R., Boonen, S., Cauley, J.A., et al. (2007) Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. The New England Journal of Medicine, 356, 1809-1822. https://doi.org/10.1056/NEJMoa067312
|
[89]
|
Recker, R.R., Delmas, P.D., Halse, J., Reid, I.R., Boonen, S., García-Hernandez, P.A., et al. (2008) Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure. Journal of Bone and Mineral Research, 23, 6-16. https://doi.org/10.1359/jbmr.070906
|
[90]
|
Delmas, P.D., Munoz, F., Black, D.M., Cosman, F., Boonen, S., Watts, N.B., et al. (2009) Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP with Fracture Reduction in Postmenopausal Women with Osteoporosis. Journal of Bone and Mineral Research, 24, 1544-1551. https://doi.org/10.1359/jbmr.090310
|
[91]
|
Black, D.M., Reid, I.R., Boonen, S., Bucci-Rechtweg, C., Cauley, J.A., Cosman, F., et al. (2012) The Effect of 3 versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the Horizon-Pivotal Fracture Trial (PFT). Journal of Bone and Mineral Research, 27, 243-254. https://doi.org/10.1002/jbmr.1494
|
[92]
|
Cosman, F., Cauley, J.A., Eastell, R., Boonen, S., Palermo, L., Reid, I.R., et al. (2014) Reassessment of Fracture Risk in Women after 3 Years of Treatment with Zoledronic Acid: When Is It Reasonable to Discontinue Treatment? The Journal of Clinical Endocrinology & Metabolism, 99, 4546-4554. https://doi.org/10.1210/jc.2014-1971
|
[93]
|
Black, D.M., Reid, I.R., Cauley, J.A., Cosman, F., Leung, P.C., Lakatos, P., et al. (2015) The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Secondextension to the Horizon-Pivotal Fracture Trial (PFT). American Society for Bone and Mineral Research, 30, 934-944. https://doi.org/10.1002/jbmr.2442
|
[94]
|
Grey, A., Bolland, M.J., Wattie, D., Horne, A., Gamble, G. and Reid, I.R. (2009) The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. The Journal of Clinical Endocrinology & Metabolism, 94, 538-544. https://doi.org/10.1210/jc.2008-2241
|
[95]
|
Greenspan, S.L., Perera, S., Ferchak, M.A., Nace, D.A. and Resnick, N.M. (2015) Efficacy and Safety of Single-Dose Zoledronic Acid for Osteoporosis in Frail Elderly Women a Randomized Clinical Trial. Journal of the American Medical Association, 175, 913-921.
|
[96]
|
Boonen, S., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., et al. (2012) Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis. The New England Journal of Medicine, 367, 1714-1732. https://doi.org/10.1056/NEJMoa1204061
|
[97]
|
Lekamwasam, S., Adachi, J.D., Agnusdei, D., Bilezikian, J., Boonen, S., Borgström, F., et al. (2012) A Framework for the Development of Guidelines for the Management of Glucocorticoid-Induced Osteoporosis. Osteoporosis International, 23, 2257-2276. https://doi.org/10.1007/s00198-012-1958-1
|
[98]
|
Wellington, K., Goa, K.L., Coleman, R.E., Dearnaley, D.R., Fleisch, H. and Hotte, S.J. (2003) Zoledronic Acid: A Review of Its Use in the Management of Bone Metastases and Hypercalcaemia of Malignancy. Drugs, 63, 417-437. https://doi.org/10.2165/00003495-200363040-00009
|
[99]
|
Wood, J., Bonjean, K., Ruetz, S., Ene, A.B., Devy, L., Foidart, J.M., et al. (2002) Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid. Journal of Pharmacology and Experimental Therapeutics, 302, 1055-1061. https://doi.org/10.1124/jpet.102.035295
|
[100]
|
Reid, I.R., Gamble, G.D., Mesenbrink, P., Lakatos, P. and Black, D.M. (2010) Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid. The Journal of Clinical Endocrinology & Metabolism, 95, 4380-4387. https://doi.org/10.1210/jc.2010-0597
|
[101]
|
Rathbone, E.J., Brown, J.E., Marshall, H.C., Collinson, M., Liversedge, V., Murden, G.A., et al. (2013) Osteonecrosis of the Jaw and Oral Health-Related Quality of Life after Adjuvant Zoledronic Acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial Subprotocol (BIG01/04). Journal of Clinical Oncology, 31, 2685-2691. https://doi.org/10.1200/JCO.2012.46.4792
|
[102]
|
Grbic, J.T., Black, D.M., Lyles, K.W., Reid, D.M., Orwoll, E., McClung, M., et al. (2010) The Incidence of Osteonecrosis of the Jaw in Patients Receiving 5 Milligrams of Zoledronic Acid: Data from the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Clinical Trials Program. The Journal of the American Dental Association, 141, 1365-1370. https://doi.org/10.14219/jada.archive.2010.0082
|
[103]
|
Güzelant, A.Y., Sarifakioglu, A.B., Yilmaz, I., Alpsoy, S., Sara çoglu, G.V. and Tasdemir, N. (2016) Should the Cardiac Rhythm Be Monitored Following Administration of Zoledronic Acid in Elderly Osteoporotic Women? Turkish Journal of Physical Medicine and Rehabilitation, 62, 214-221.
|